Well, that’s an issue that’s very close to my heart. I think it’s very exciting. It’s not a therapeutic outcome, but it’s the deployment of advanced image analysis, and as you said, wearable devices and digital devices like cell phones and smart watches to better understand and monitor disease progression in patients. One issue we have with some of the trials is that we lack the adequate means to measure therapeutic effects...
Well, that’s an issue that’s very close to my heart. I think it’s very exciting. It’s not a therapeutic outcome, but it’s the deployment of advanced image analysis, and as you said, wearable devices and digital devices like cell phones and smart watches to better understand and monitor disease progression in patients. One issue we have with some of the trials is that we lack the adequate means to measure therapeutic effects. And I think that the progress in digital methodologies has been so rapid that we as a community of, let’s say, trial designers have to catch up and take full advantage of the technologies that are already available. I’m very happy that this is being done. And that’s one of the outcomes that comes out of what you called failed trials, yeah, is that digital biomarkers have been used there. We’ve learned what the advantages and disadvantages are. And so regardless of whether we were able to show a therapeutic effect, they will definitely help us design better trials.